UPDATE: JPMorgan Upgrades Esperion Therapeutics (ESPR) to Neutral Citing 'Achievable Estimates as Outcomes Data Nears'

JPMorgan analyst Jessica Fye upgraded Esperion Therapeutics (NASDAQ: ESPR) from Underweight to Neutral with a price target of $6.00.

The analyst comments "We are updating our model following ESPR’s 1Q earnings and upgrading our rating from Underweight to Neutral with a $6 Dec 2022 price target. While the initial Nexletol/Nexlizet launch did not materialize as some had hoped, with 2022 revenue estimates looking achievable, top-line data for CLEAR Outcomes less than a year away (we expect early 2023 given the pace of event accumulation), and sufficient cash to fund the company through that event, we see fewer reasons for underperformance."

For an analyst ratings summary and ratings history on Esperion Therapeutics click here. For more ratings news on Esperion Therapeutics click here.

Shares of Esperion Therapeutics closed at $6.53 yesterday.

You May Also Be Interested In

• JPMorgan Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• HSBC Upgrades Sembcorp Industries (SCI:SP) to Buy
• JPMorgan Downgrades ASX Limited (ASX:AU) (ASXFY) to Neutral